Navigation Links
Neurologix Announces Second Quarter 2011 Financial Results
Date:8/11/2011

lating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through June 30, 2011, it incurred net losses and negative cash flows from operating activities of approximately $63.0 million and $48.9 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2011, the Company had cash and cash equivalents of approximately $3.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan o
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
    2. Bion Announces New U.S. Patent for Phosphorus Removal
    3. ViaCyte Announces Executive Management Changes
    4. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSELā„¢ Technology Being Developed to Treat Osteoporosis
    5. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
    6. Osteologix Announces Completion of Corporate Consolidation
    7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
    8. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
    9. Rigel Announces Second Quarter 2011 Financial Results
    10. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
    11. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
    (Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
    (Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   ... will be a 177-key, 4-star boutique hotel in the heart of ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... first hotel within ATLAS , The ... of standard rooms and suites, a sleek restaurant and bar, a ...
    (Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
    Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
    ... LESS Instrumentation Is Selected for Industry Leader LESS Panel ... 29 Cambridge Endo, a pioneer in the rapidly ... or SPA) market, is pleased to announce that its ... leaders selected to be on a LESS panel at ...
    ... Laboratory InstrumentsMENLO PARK, Calif. and NORWOOD, Mass., Jan. ... today jointly announced that Advanced Instruments Inc. has ... The two companies further announced their intention ... generation of laboratory instruments for osmolality measurement, incorporating ...
    ... N.J., Jan. 29 Amicus Therapeutics (Nasdaq: ... 2008 financial results after the regular close of markets ... be followed by a live conference call and webcast ... investors may access the conference call at 5 p.m. ...
    Cached Biology Technology:Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009 2Advanced Instruments Makes Strategic Investment in Cantimer, Inc. 2Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
    (Date:7/28/2014)... ago, MIT professor John Essigmann and colleagues from the University ... They thought if they could induce the virus to mutate ... out a strategy that our immune system uses against ... which caused HIV to mutate at an enhanced rate, as ... in a small clinical trial reported in 2011. In a ...
    (Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
    (Date:7/28/2014)... MANHATTAN, Kansas He calls himself the bug hunter, ... that can only be found and identified with special ... at the Kansas State Veterinary Diagnostic Laboratory at Kansas ... his discoveries, porcine enterovirus G, which is an important ... a virus in cells, but didn,t know what it ...
    Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
    ... CORVALLIS, Ore. Researchers at Oregon State University ... the collapse of oyster seed production at a commercial ... to a level considered by the owners to be ... that elevated seawater carbon dioxide (CO2) levels, resulting in ...
    ... Mass. Copper the stuff of pennies and tea ... can turn carbon dioxide into hydrocarbon fuels with relatively little ... copper acts as a strong catalyst, setting off an electrochemical ... methane or methanol. Various researchers around the world have ...
    ... CO, USA -- April 10, 2012 -- HUNT Biosciences ... advance the clinical use of protein biomarkers, with an ... prediction of cardiovascular events such as strokes, heart attacks, ... samples and clinical data from HUNT Biosciences using SomaLogic,s ...
    Cached Biology News:Ocean acidification linked to larval oyster failure 2Ocean acidification linked to larval oyster failure 3Hybrid copper-gold nanoparticles convert CO2 2Hybrid copper-gold nanoparticles convert CO2 3
    Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
    Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
    WNV Core Antibody...
    ... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from within ... FANCM. (Note: the amino acid sequence ... as ab27787 .) ...
    Biology Products: